Guardant Health, Inc. (GH) fair value analysis
Nasdaq · Updated 2026-10-19
GH price how computed
Valuation status
No fair-value estimate yetGH has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for GH yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $158.60
- Sector
- Healthcare
- 12-month range
- $69.35–$187.22
- Market cap
- $21.3B
- From 52-week high
- -15.3%
- Shares outstanding
- 134M
- Rank in Healthcare by quality score
- #101 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Guardant Health, Inc. is a healthcare company that specializes in developing and commercializing blood tests and other diagnostic tools for detecting cancer and monitoring cancer patients. The company operates globally, providing its liquid biopsy testing services and platforms to healthcare providers and patients across multiple countries.
GH currently ranks #101 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $21.3B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $1.18B
- Net margin
- -38.3%
- EPS (TTM)
- $-2.23
- Gross margin
- 65.4%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 44.7%
- Shares outstanding
- 134M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 32 · neutral
- 50-day average
- $168.08
- 200-day average
- $127.26
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05 (post-market)
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-20.3%)
2026-03 ▲ beat (+4.3%)
2025-12 ▼ miss (-6.4%)
2025-09 ▲ beat (+20.4%)
2025-06 ▲ beat (+13.7%)
2025-03 ▲ beat (+16.9%)
2024-12 ▼ miss (-23.1%)
2024-09 ▼ miss (-18.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 25 buy · 0 hold · 1 sell (26 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $202
- Target vs last price
- +27.4%
What our data shows for GH
- Shares are trading in the upper third of their 12-month price range of $69.35–$187.22.
- The 14-day relative strength index sits at a neutral 32.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- GH's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the GH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for GH in the Healthcare sector showed a notable shift this week as the 50/200-day trend state transitioned from an uptrend to mixed conditions. This change reflects a loss of momentum in the intermediate-term price trajectory for the sector. The current valuation verdict remains awaiting full valuation.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is GH stock undervalued?
TickrTrends has no fair-value estimate for GH yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is GH's TickrTrends verdict?
GH is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does GH compare to other Healthcare stocks?
GH ranks #101 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is GH overbought or oversold?
GH's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does GH report earnings next?
GH's next earnings report is scheduled for 2026-11-05 (post-market), per the published earnings calendar.
Does GH usually beat earnings estimates?
Over its last 8 reported quarters GH beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about GH?
Of 26 analysts covering GH, 25 rate it a buy, 0 a hold and 1 a sell - buy-leaning, with a consensus price target of $202 (+27.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.